Affiliation:
1. Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK
Abstract
For patients presenting with acute or chronic coronary syndromes, current guideline recommendations and expert consensus provide a range of options for antithrombotic treatment. The European Society of Cardiology 2023 guidelines on the management of acute coronary syndrome emphasise the need to assess the risk of both ischaemic events and bleeding. Those with high bleeding risk warrant particular consideration of the duration and intensity of antithrombotic therapy combinations. A joint consensus of experts takes a similar approach, informed by two network meta-analyses that appraised all available antithrombotic treatments within or after the 12 months following coronary revascularisation and/or acute coronary syndrome and individual participant data from six trials. In this article, four case studies are used to illustrate how these guidelines and expert consensus recommendations can be applied in clinical practice.
Publisher
Radcliffe Media Media Ltd
Reference6 articles.
1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–77. https://doi.org/10.1093/eurheartj/ehz425; PMID: 31504439.
2. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191; PMID: 37622654.
3. Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019;140:240–61. https://doi.org/10.1161/CIRCULATIONAHA.119.040167; PMID: 31116032.
4. Valgimigli M, Aboyans V, Angiolillo D, et al. Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. Eur Heart J Cardiovasc Pharmacother 2023;9:462–96. https://doi.org/10.1093/ehjcvp/pvad032; PMID: 37120728.
5. Crea F, Thiele H, Sibbing D, et al. Debate: prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. Eur Heart J 2021;42:2973–85. https://doi.org/10.1093/eurheartj/ehab277; PMID: 34110420.